Malaria vaccine trials in pregnant women: An imperative without precedent

Enrolling Women into HIV Preventive Vaccine Trials: An Ethical Imperative but a Logistical Challenge

March 2006 | Volume 3 | Issue 3 | e94 With almost 5 million new HIV infections and 3 million deaths from AIDS occurring every year worldwide, the development of a safe, effective, and accessible HIV vaccine has become one of the most urgent global public health needs. The United Nations estimates that 17.5 million women between the ages of 15 and 49 years are living with HIV, accounting for nea...

malaria in pregnant women

Preventing malaria in HIV-infected pregnant women.

Efforts to curb or eliminate malaria incidence in areas with a high prevalence of human immunodeficiency virus (HIV) face many challenges, chief among which are inconsistent access to proven interventions and limited resources of prevention and control programs. These challenges are compounded by the fact that HIV and malaria interact synergistically, with HIV increasing the risk and severity o...

The Treatment of Malaria in Pregnant Women

Mefloquine for preventing malaria in pregnant women

BACKGROUND The World Health Organization recommends intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine for malaria for all women who live in moderate to high malaria transmission areas in Africa. However, parasite resistance to sulfadoxine-pyrimethamine has been increasing steadily in some areas of the region. Moreover, HIV-infected women on cotrimoxazole proph...